Pacer Advisors Inc. Grows Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Pacer Advisors Inc. increased its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 32.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,070,434 shares of the company’s stock after purchasing an additional 508,789 shares during the quarter. Pacer Advisors Inc. owned 4.51% of Omnicell worth $56,047,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in shares of Omnicell by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after buying an additional 80,312 shares in the last quarter. Champlain Investment Partners LLC grew its holdings in Omnicell by 16.0% during the 1st quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock worth $51,246,000 after acquiring an additional 241,235 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Omnicell by 0.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock valued at $31,955,000 after purchasing an additional 3,570 shares during the last quarter. Federated Hermes Inc. raised its holdings in shares of Omnicell by 1,113.6% in the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after purchasing an additional 909,480 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Omnicell by 61.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock valued at $16,240,000 after purchasing an additional 228,093 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Trading Up 2.8 %

Shares of Omnicell stock opened at $44.62 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45. The company has a market capitalization of $2.05 billion, a P/E ratio of -97.00, a PEG ratio of 49.47 and a beta of 0.83. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $53.37. The company’s fifty day moving average is $39.21 and its two-hundred day moving average is $32.28.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The firm’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same period last year, the firm earned $0.29 EPS. Analysts forecast that Omnicell, Inc. will post 0.64 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on OMCL shares. Benchmark reissued a “buy” rating and issued a $38.00 target price on shares of Omnicell in a report on Monday, July 15th. Wells Fargo & Company increased their price objective on Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. Barclays upgraded Omnicell from an “underweight” rating to an “equal weight” rating and boosted their target price for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. JPMorgan Chase & Co. upped their price target on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Finally, StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a report on Thursday. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $37.83.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.